Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sino Biopharmaceutical
Fierce Pharma
Sanofi inks $1.5B deal for Sino Biopharm's novel asset
Sanofi is committing $1.53 billion to license a first-in-class JAK/ROCK inhibitor from Sino Biopharm with eyes on both hematology and immunology.
Angus Liu
Mar 4, 2026 3:00am
AI-driven Formation snaps up oral autoimmune asset in $500M play
Jan 29, 2026 1:20pm
Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova
Jul 15, 2025 10:16am
F-star breaks free from invoX after $161M acquisition
Apr 4, 2025 10:03am
Takeda adds F-Star collab to constellation worth up to $1B
Jul 5, 2023 2:00pm
